The latest update on NKTR-214/Opdivo from Nektar and Bristol-Myers will keep the controversy burning over the ORR rate
Nektar Therapeutics $NKTR managed to slide 1 out of its 38 evaluable stage 4 melanoma patients into the win column with its closely-watched 3-month update on Opdivo/NKTR-214’s objective response rate. That managed to nudge up the ORR from 50% — a figure that routed Nektar’s stock at ASCO — to 53%, which isn’t likely to convince any of the critics that the biotech and its partners at Bristol-Myers Squibb have come up with the kind of combo that can change the standard of care in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
